LU93078I2 - Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib - Google Patents

Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib Download PDF

Info

Publication number
LU93078I2
LU93078I2 LU93078C LU93078C LU93078I2 LU 93078 I2 LU93078 I2 LU 93078I2 LU 93078 C LU93078 C LU 93078C LU 93078 C LU93078 C LU 93078C LU 93078 I2 LU93078 I2 LU 93078I2
Authority
LU
Luxembourg
Prior art keywords
solvates
pharmaceutically acceptable
acceptable salts
combimetinib
possibly
Prior art date
Application number
LU93078C
Other languages
English (en)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37728416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of LU93078I2 publication Critical patent/LU93078I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
LU93078C 2005-10-07 2016-05-19 Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib LU93078I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72457805P 2005-10-07 2005-10-07
US80284006P 2006-05-23 2006-05-23
PCT/US2006/039126 WO2007044515A1 (fr) 2005-10-07 2006-10-05 Inhibiteurs de mek et procedes pour les utiliser

Publications (1)

Publication Number Publication Date
LU93078I2 true LU93078I2 (fr) 2016-07-19

Family

ID=37728416

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93078C LU93078I2 (fr) 2005-10-07 2016-05-19 Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib

Country Status (32)

Country Link
US (9) US7803839B2 (fr)
EP (1) EP1934174B1 (fr)
JP (8) JP5129143B2 (fr)
KR (2) KR20130058072A (fr)
CN (5) CN109053523B (fr)
AT (1) ATE504565T1 (fr)
AU (1) AU2006302415B2 (fr)
BE (1) BE2016C029I2 (fr)
BR (1) BRPI0617165B1 (fr)
CA (3) CA2927656C (fr)
CY (2) CY1111670T1 (fr)
DE (1) DE602006021205D1 (fr)
DK (1) DK1934174T3 (fr)
EA (3) EA025871B9 (fr)
ES (1) ES2365070T3 (fr)
FR (1) FR16C0021I2 (fr)
GE (1) GEP20125456B (fr)
HR (1) HRP20110498T1 (fr)
HU (1) HUS1600021I1 (fr)
IL (5) IL189900A (fr)
LT (1) LTC1934174I2 (fr)
LU (1) LU93078I2 (fr)
MY (1) MY162174A (fr)
NL (1) NL300809I2 (fr)
NO (4) NO347091B1 (fr)
NZ (1) NZ567140A (fr)
PL (1) PL1934174T3 (fr)
PT (1) PT1934174E (fr)
RS (1) RS51782B (fr)
SI (1) SI1934174T1 (fr)
WO (1) WO2007044515A1 (fr)
ZA (1) ZA200802075B (fr)

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
DE602006021205D1 (de) * 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
JP2010500994A (ja) * 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
WO2008055236A2 (fr) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase mapk/erk
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
WO2008124085A2 (fr) * 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
EP2155666A1 (fr) * 2007-05-10 2010-02-24 Pfizer Limited Dérivés d'azétidine et leur utilisation comme antagonistes des prostaglandines e2
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
EP2307364B1 (fr) 2008-07-01 2013-06-19 Genentech, Inc. Dérivés d'isoindolone utilisés en tant qu'inhibiteurs de kinase mek et procédés d'utilisation correspondants
EP2310373A1 (fr) 2008-07-01 2011-04-20 Genentech, Inc. Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
JP5546636B2 (ja) 2009-09-28 2014-07-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
RU2654068C1 (ru) 2009-09-28 2018-05-16 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3 и способы применения
US20110086837A1 (en) * 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
EA201200651A1 (ru) * 2009-11-04 2012-12-28 Новартис Аг Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
WO2011069074A2 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Procédés de traitement de cancer du sein métastasique avec trastuzumab-mcc-dm1
EP2526102B1 (fr) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibiteurs de la PI3 kinase
EP2539337A1 (fr) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Composés de pyrido[3,2-d]pyrimidine inhibiteurs de pi3k delta et procédés d'utilisation
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
WO2011121317A1 (fr) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo[1,2-b][1,2,3]thiadiazoles en tant qu'inhibiteurs de la kinase protéique ou de la kinase lipidique
SG184475A1 (en) 2010-04-07 2012-11-29 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
CN110818724B (zh) 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
CA2802808A1 (fr) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Composes de purine selectifs de la pi3k p110 delta, et procedes d'utilisation
EP2598661B1 (fr) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
WO2012018638A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
JP5842004B2 (ja) 2010-09-01 2016-01-13 ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． ピリダジノン、その製造方法及びその使用方法
US9249123B2 (en) 2010-09-01 2016-02-02 Genentech, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
WO2012052745A1 (fr) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral
US20140080810A1 (en) 2010-11-15 2014-03-20 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
CA2820078C (fr) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Composes tricycliques inhibiteurs de pi3k et procedes d'utilisation
JP5766820B2 (ja) 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤としての複素環化合物
MX340013B (es) 2011-03-21 2016-06-22 Hoffmann La Roche Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
CN102718750B (zh) * 2011-03-31 2015-03-11 中国人民解放军军事医学科学院毒物药物研究所 含吖啶环的氨基吡啶类衍生物及其用途
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
KR101953210B1 (ko) 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
EP2524918A1 (fr) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines en tant qu'inhibiteurs de kinase
AR086647A1 (es) 2011-06-03 2014-01-15 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
BR112014003296A2 (pt) 2011-08-12 2017-03-14 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
US8614206B2 (en) 2011-09-27 2013-12-24 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2013055987A1 (fr) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
CA2850034A1 (fr) * 2011-10-28 2013-05-02 Genentech, Inc. Associations therapeutiques et methodes de traitement du melanome
RU2622391C2 (ru) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
BR112014010439A2 (pt) 2011-11-03 2017-04-18 F Hoffmann - La Roche Ag compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2592103A1 (fr) 2011-11-08 2013-05-15 Adriacell S.p.A. Dérivés d'aldéhyde de polymère
CN104302669A (zh) 2011-11-23 2015-01-21 伊格尼卡生物治疗公司 抗cd98抗体及其使用方法
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
US9897607B2 (en) 2012-02-01 2018-02-20 The Governors Of The University Of Alberta Methods, kits, and systems for treatment of metastatic papillary thyroid cancer
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
EP2867232B1 (fr) 2012-06-27 2018-08-08 F.Hoffmann-La Roche Ag Composés de 5-azaindazole et procédés d'utilisation
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
CA2882292C (fr) * 2012-08-13 2023-10-17 The Rockefeller University Traitement et diagnostic du melanome
SI2884979T1 (sl) 2012-08-17 2019-10-30 Hoffmann La Roche Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
CN104583215B (zh) 2012-08-30 2016-12-07 霍夫曼-拉罗奇有限公司 二噁烯并-和噁嗪-[2,3-d]嘧啶pi3k抑制剂化合物及使用方法
JP6666147B2 (ja) 2012-09-26 2020-03-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 環状エーテルピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
CA2887129A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs methodes d'utilisation
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014057117A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazépine-anticorps
HRP20181646T2 (hr) 2012-10-12 2019-08-09 Adc Therapeutics Sa Konjugati pirolobenzodiazepin - anti-psma protutijela
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
JP6300042B2 (ja) * 2012-10-12 2018-03-28 エグゼリクシス， インコーポレイテッド 癌の処置に使用するための化合物の製造方法
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
HRP20190366T1 (hr) 2012-10-12 2019-04-19 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
WO2014074785A1 (fr) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Procédés de prédiction de l'issue et du traitement du cancer du sein
CA2889381C (fr) * 2012-11-15 2023-01-03 Duquesne University Of The Holy Ghost Inhibiteurs de mek sous forme de promedicaments a base d'ester d'acide carboxylique
TW201441193A (zh) * 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
EP2934572A4 (fr) 2012-12-20 2016-11-23 Biomatrica Inc Formulations et procédés pour stabiliser des réactifs pcr
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
EP2958592A1 (fr) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Méthodes de traitement du cancer et de prévention de résistance aux médicaments
US10139415B2 (en) 2013-02-27 2018-11-27 Daiichi Sankyo Company, Limited Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
EP2968585B1 (fr) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
BR112015022576A2 (pt) 2013-03-14 2017-10-24 Genentech Inc produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
IL283717B (en) 2013-03-15 2022-09-01 Cancer Research Tech Llc Methods and compositions for gamma-glutamyl cycle modulation
WO2014153495A2 (fr) 2013-03-22 2014-09-25 University Of Hawaii Nouveaux inhibiteurs de stats3
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
EP3007556B1 (fr) 2013-06-13 2020-05-20 Biomatrica, INC. Stabilisation de cellules
WO2015000949A1 (fr) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Composés hétéroaryl pyridone et aza-pyridone amide
WO2015031698A1 (fr) 2013-08-28 2015-03-05 Stem Centrx, Inc. Procédés de conjugaison d'anticorps régiospécifiques et compositions
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
SG11201510740YA (en) 2013-09-17 2016-01-28 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3077384B1 (fr) 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile
WO2015108203A1 (fr) 2014-01-15 2015-07-23 株式会社オーダーメードメディカルリサーチ Composition pharmaceutique thérapeutique utilisant un anticorps anti-slc6a6
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
KR20160127140A (ko) 2014-03-18 2016-11-02 에프. 호프만-라 로슈 아게 옥세판-2-일-피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10266603B2 (en) 2014-04-18 2019-04-23 The Governors Of The University Of Alberta Targeted therapy to restore radioactive iodine transport in thyroid cancer
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2015172073A1 (fr) 2014-05-08 2015-11-12 Cornell University Gels bioadhésifs et procédés d'utilisation
WO2015182734A1 (fr) * 2014-05-30 2015-12-03 協和発酵キリン株式会社 Composé hétérocyclique contenant de l'azote
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
EP3563870A1 (fr) 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'inhibiteurs de mek
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016044396A1 (fr) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugués comprenant des anticorps anti-her2 et des pyrrolobenzodiazépines
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN106922146B (zh) 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2970352A1 (fr) 2014-12-11 2016-06-16 Pierre Fabre Medicament Anticorps anti-c10orf54 et leurs utilisations
WO2016095088A1 (fr) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
WO2016095089A1 (fr) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP6957035B2 (ja) 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016196373A2 (fr) 2015-05-30 2016-12-08 Genentech, Inc. Procédés de traitement de cancer du sein métastatique her2 positif
EP3307780A1 (fr) 2015-06-15 2018-04-18 Genentech, Inc. Anticorps et immunoconjugués
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
EP3881833B1 (fr) 2015-06-30 2023-11-01 Genentech, Inc. Comprimés à libération immédiate contenant un médicament et procédés pour former les comprimés
EP4585597A1 (fr) 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Composés de benzoxazepine oxazolidinone et procédés d'utilisation
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2017033113A1 (fr) 2015-08-21 2017-03-02 Acerta Pharma B.V. Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
BR112018008882A8 (pt) 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN121154828A (zh) 2015-11-19 2025-12-19 豪夫迈·罗氏有限公司 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
BR112018069530B1 (pt) 2016-02-29 2021-02-17 F. Hoffmann-La Roche Ag composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
WO2017216280A1 (fr) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indoles et utilisations associées
CN109311876B (zh) 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
CN106220607B (zh) * 2016-07-27 2018-09-18 成都百事兴科技实业有限公司 一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
BR112019002036A2 (pt) 2016-08-12 2019-05-14 Genentech Inc métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018094414A1 (fr) 2016-11-21 2018-05-24 Obi Pharma, Inc. Molécules biologiques conjuguées, compositions pharmaceutiques et procédés
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SMT202200068T1 (it) 2017-02-08 2022-05-12 Adc Therapeutics Sa Coniugati di pirrolobenzodiazepina-anticorpo
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
CN106866624B (zh) * 2017-02-27 2017-12-26 济宁医学院 一种卡比替尼的化学合成方法
WO2018187478A1 (fr) 2017-04-04 2018-10-11 University Of Miami Biomarqueurs indicatifs du cancer de la prostate et traitement associé
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
WO2018193102A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polythérapie avec un conjugué anticorps anti-axl-médicament
WO2018193104A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polythérapie avec un conjugué anticorps-médicament anti-cd25
WO2018229218A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd25
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3752200A1 (fr) 2018-02-13 2020-12-23 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
US12280039B2 (en) 2018-03-21 2025-04-22 Colorado State University Research Foundation Cancer vaccine compositions and methods of use thereof
JPWO2019188595A1 (ja) 2018-03-26 2020-12-03 富士フイルム株式会社 感光性樹脂組成物及びその製造方法、レジスト膜、パターン形成方法、並びに、電子デバイスの製造方法
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
JP7590083B2 (ja) 2018-08-31 2024-11-26 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
WO2020079581A1 (fr) 2018-10-16 2020-04-23 Novartis Ag Charge mutationnelle tumorale seule ou en combinaison avec des marqueurs immunitaires comme biomarqueurs pour prédire une réponse à une thérapie ciblée
JP7546297B2 (ja) * 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CA3120351A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau
CA3120337A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes naphthyridinone-aniline destines au traitement d'affections de la peau
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
WO2020109251A1 (fr) 2018-11-29 2020-06-04 Adc Therapeutics Sa Régime posologique
WO2020127573A1 (fr) 2018-12-19 2020-06-25 Adc Therapeutics Sa Résistance à la pyrrolobenzodiazépine
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN118221763A (zh) 2019-03-29 2024-06-21 免疫医疗有限公司 化合物及其缀合物
TWI735210B (zh) 2019-04-26 2021-08-01 中國醫藥大學 Ａｄａｍ９抑制劑作為免疫調節劑之用途
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN114302745A (zh) 2019-06-10 2022-04-08 Adc治疗有限公司 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
JP2022536140A (ja) 2019-06-10 2022-08-12 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
GEP20247627B (en) 2019-07-22 2024-05-27 Lupin Ltd Macrocyclic compounds as sting agonists and methods and uses thereof
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
US20240123081A1 (en) 2019-10-25 2024-04-18 Medimmune, Llc Branched moiety for use in conjugates
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
CN111170990B (zh) * 2020-01-16 2021-01-05 广州科锐特生物科技有限公司 一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
KR20220130749A (ko) 2020-01-22 2022-09-27 메디뮨 리미티드 화합물 및 이의 접합체
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021206167A1 (fr) 2020-04-10 2021-10-14 大鵬薬品工業株式会社 Thérapie contre le cancer à l'aide d'un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de mek
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
EP3915576A1 (fr) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Récepteurs d'antigène chimérique spécifiques pour p95her2 et leurs utilisations
EP3939999A1 (fr) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
GB202012161D0 (en) 2020-08-05 2020-09-16 Adc Therapeutics Sa Combination therapy
MX2023001865A (es) 2020-08-14 2023-05-09 Guangzhou Lupeng Pharmaceutical Company Ltd Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
GB202015226D0 (en) 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
GB202015916D0 (en) 2020-10-07 2020-11-18 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20240173329A1 (en) 2021-03-09 2024-05-30 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
EP4308935A1 (fr) 2021-03-18 2024-01-24 Novartis AG Biomarqueurs pour le cancer et leurs méthodes d'utilisation
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
GB202107709D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
GB202107713D0 (en) 2021-05-28 2021-07-14 Medimmune Ltd Combination therapy
GB202107706D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
KR102699226B1 (ko) 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
MX2023015264A (es) 2021-06-29 2024-01-19 Adc Therapeutics Sa Terapia de combinaicon con conjugados de anticuerpo-farmaco.
WO2023057545A1 (fr) 2021-10-06 2023-04-13 Microquin Ltd. Chalcones substitués
WO2023078881A1 (fr) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Nouvelle utilisation d'un composé quinazolinone pour le traitement du cancer
EP4436570A4 (fr) 2021-11-23 2025-10-22 Nflection Therapeutics Inc Formulations de composés de pyrrolopyridine-aniline
JP2025503456A (ja) 2021-12-16 2025-02-04 アールディーピー ファーマ アーゲー 細胞膜透過性ポリペプチド（ｃｐｐ）及びヒト治療におけるそれらの使用
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
EP4493169A4 (fr) * 2022-03-17 2026-03-04 Springworks Therapeutics Inc Composés phénylamino fluorés et compositions pharmaceutiques
EP4253418A1 (fr) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Cellules immunitaires exprimant des récepteurs d'antigène chimérique et anticorps bispécifiques et leurs utilisations
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
WO2024033381A1 (fr) 2022-08-10 2024-02-15 Vib Vzw Inhibition de tcf4/itf2 dans le traitement du cancer
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
EP4406973A1 (fr) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Anticorps et leurs utilisations pour le traitement d'infections provoquées par des virus enveloppés
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025029650A1 (fr) 2023-07-28 2025-02-06 Li Xiyan Régimes nutritionnels modifiés comprenant des aminoacides destinés à être utilisés dans le traitement d'une maladie
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026019990A1 (fr) 2024-07-18 2026-01-22 Genentech, Inc. Méthodes de traitement du cancer avec des anticorps bispécifiques anti-ccr8/anti-cd3
WO2026024841A1 (fr) 2024-07-24 2026-01-29 Astellas Us Llc Anticorps bispécifiques qui se lient à cd3 et muc1 et leurs procédés d'utilisation
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
JPH03192592A (ja) 1989-12-21 1991-08-22 Matsushita Electric Ind Co Ltd 磁気テープ記録再生装置
AU685933B2 (en) 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (fr) 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
NZ501277A (en) * 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
WO2000035435A1 (fr) 1998-12-15 2000-06-22 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
EP1143957A3 (fr) 1998-12-16 2002-02-27 Warner-Lambert Company Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
ES2253928T3 (es) 1998-12-22 2006-06-01 Warner-Lambert Company Llc Quimioterapia de combinacion que comprende un inhibidor mitotico y un inhibidor mek.
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
EP1140062B1 (fr) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Traitement de l'asthme a l'aide d'inhibiteurs de mek
IL144103A0 (en) 1999-01-07 2002-05-23 Warner Lambert Co Antiviral method using mek inhibitors
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
AU2482700A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 1-heterocycle substituted diarylamines
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
WO2000041505A2 (fr) * 1999-01-13 2000-07-20 Warner-Lambert Company 4'heteroaryle diarylamines
CN1365277A (zh) 1999-07-16 2002-08-21 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
KR20020015379A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 엠이케이 억제제를 사용하는 만성 동통의 치료방법
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
CA2377092A1 (fr) 1999-07-16 2001-01-25 Warner-Lambert Company Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
CA2403017A1 (fr) 2000-03-15 2001-09-20 Warner-Lambert Company Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CA2416685C (fr) 2000-07-19 2008-10-07 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
JP2003192592A (ja) 2001-10-17 2003-07-09 Sankyo Co Ltd 医薬組成物
CA2460118A1 (fr) 2001-10-31 2003-05-08 Pfizer Products Inc. Agonistes du recepteur d'acetylcholine nicotinique pour traiter les impatiences des membres inferieurs
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60330227D1 (de) * 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
WO2003103590A2 (fr) 2002-06-11 2003-12-18 Merck & Co., Inc. Inhibiteurs de la kinase p38 (halo-benzo carbonyl)heterobicyclique
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1641804A1 (fr) 2003-06-20 2006-04-05 Celltech R & D Limited Derives de thienopyridone en tant qu inhibiteurs de kinase
WO2005000818A1 (fr) 2003-06-27 2005-01-06 Warner-Lambert Company Llc Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005007616A1 (fr) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Derives de diphenylaminocetone utiles comme inhibiteurs de mek
EP1651214B1 (fr) * 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazoles n-methyle-substitues
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
WO2005028426A1 (fr) 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4527729B2 (ja) * 2003-12-08 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー 新規チアゾール誘導体
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
PE20060572A1 (es) 2004-07-27 2006-06-27 Novartis Ag Compuestos de benzoimidazolona como inhibidores de hsp90
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2006061712A2 (fr) 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DE602006021205D1 (de) * 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JP2010500994A (ja) * 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法

Also Published As

Publication number Publication date
HK1119698A1 (en) 2009-03-13
DK1934174T3 (da) 2011-08-01
HUS1600021I1 (hu) 2016-06-28
US20170166523A9 (en) 2017-06-15
JP2018058907A (ja) 2018-04-12
IL251185A0 (en) 2017-05-29
EA025871B1 (ru) 2017-02-28
PL1934174T3 (pl) 2011-09-30
JP2014111659A (ja) 2014-06-19
NO347091B1 (no) 2023-05-15
ES2365070T3 (es) 2011-09-21
AU2006302415A1 (en) 2007-04-19
CY2016015I2 (el) 2016-10-05
IL229136A (en) 2015-11-30
CN104892582A (zh) 2015-09-09
US20200031770A1 (en) 2020-01-30
PT1934174E (pt) 2011-07-14
EA201400111A1 (ru) 2014-09-30
EP1934174A1 (fr) 2008-06-25
CA2622755A1 (fr) 2007-04-19
CN104892582B (zh) 2019-09-27
EA200801041A1 (ru) 2009-02-27
CN110668988A (zh) 2020-01-10
EA025871B9 (ru) 2017-08-31
CA2622755C (fr) 2017-01-31
NO2023022I1 (no) 2023-05-11
HRP20110498T1 (hr) 2011-08-31
GEP20125456B (en) 2012-03-26
US20250100966A1 (en) 2025-03-27
EA019983B1 (ru) 2014-07-30
US20150141399A1 (en) 2015-05-21
EP1934174B1 (fr) 2011-04-06
MY162174A (en) 2017-05-31
CN103524392B (zh) 2018-06-01
IL233053A0 (en) 2014-07-31
DE602006021205D1 (de) 2011-05-19
CN101365676A (zh) 2009-02-11
KR101341792B1 (ko) 2013-12-23
JP2017101071A (ja) 2017-06-08
US11597699B2 (en) 2023-03-07
EA201691142A1 (ru) 2017-02-28
FR16C0021I1 (fr) 2016-06-24
CN101365676B (zh) 2013-09-11
IL229136A0 (en) 2013-12-31
US7803839B2 (en) 2010-09-28
RS51782B (sr) 2011-12-31
US20110263558A1 (en) 2011-10-27
ATE504565T1 (de) 2011-04-15
BE2016C029I2 (fr) 2026-01-14
CN109053523B (zh) 2022-03-25
US8362002B2 (en) 2013-01-29
JP2013014601A (ja) 2013-01-24
KR20080050601A (ko) 2008-06-09
CN109053523A (zh) 2018-12-21
JP5678019B2 (ja) 2015-02-25
AU2006302415B2 (en) 2012-09-13
EA032466B1 (ru) 2019-05-31
NO20200035A1 (no) 2008-06-17
US20090156576A1 (en) 2009-06-18
NL300809I2 (fr) 2016-10-19
BRPI0617165B1 (pt) 2023-10-03
FR16C0021I2 (fr) 2017-04-14
NO2020031I1 (no) 2020-09-04
CA2927656A1 (fr) 2007-04-19
IL260127A (en) 2018-07-31
JP2019089841A (ja) 2019-06-13
LTPA2016016I1 (lt) 2016-06-10
WO2007044515A1 (fr) 2007-04-19
HK1214595A1 (zh) 2016-07-29
CA3052368A1 (fr) 2007-04-19
IL189900A (en) 2014-06-30
CY1111670T1 (el) 2015-10-07
US20200283383A1 (en) 2020-09-10
CY2016015I1 (el) 2016-10-05
US20140275527A1 (en) 2014-09-18
NZ567140A (en) 2011-09-30
SI1934174T1 (sl) 2011-08-31
JP5129143B2 (ja) 2013-01-23
JP5856211B2 (ja) 2016-02-09
IL189900A0 (en) 2008-08-07
US7915250B2 (en) 2011-03-29
CN103524392A (zh) 2014-01-22
JP2009511490A (ja) 2009-03-19
LTC1934174I2 (lt) 2018-01-10
KR20130058072A (ko) 2013-06-03
JP2020189882A (ja) 2020-11-26
IL260127B (en) 2022-04-01
NO20082088L (no) 2008-06-17
US20100249096A1 (en) 2010-09-30
CA2927656C (fr) 2019-09-24
NO344876B1 (no) 2020-06-08
ZA200802075B (en) 2009-08-26
US20190144382A1 (en) 2019-05-16
BRPI0617165A2 (pt) 2015-01-06
JP2015232045A (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
LU93078I2 (fr) Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
TW200613243A (en) Novel compounds
IL189666A0 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
MX2010003868A (es) Cis-imidazolinas quirales.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
TW200508207A (en) New benzimidazole derivatives
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
SE0402925D0 (sv) Novel Compounds
TW200639156A (en) New compounds
UA96742C2 (en) Mek inhibitors and use thereof
EA201990219A3 (ru) Ингибиторы mek и способы их применения
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf
UA95250C2 (ru) Пиридинаминосульфонил-замещенные бензамиды как ингибиторы цитохром р450 3а4 (cyp4503a4)